FDA Drugs (New Approvals & NDA)Original article
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
Positive
AI Analysis
Summary
The FDA's Center for Drug Evaluation and Research (CDER) launched the LEADER 3D initiative under the Accelerating Rare disease Cures (ARC) Program to provide learning and education resources for rare disease drug developers.
Importance:2/10
Sentiment:
0.30
rare diseaseFDACDEReducation initiativeARC Program
Read the original article
Published by FDA Drugs (New Approvals & NDA) on August 6, 2026 1:08 PM